Scientists from China discovered the effect of tumor protein on cystitis glandularis development

Cystitis glandularis is a urinary bladder disorder characterized by chronic inflammation and rapid cell division, which leads to the progression of bladder cancer. Scientists from the Shaoxing University and Wenzhou Medical University investigated the involvement of the tumor protein TPRG1 in cystitis glandularis, since it has been linked to the cell response to inflammation and its dysregulation in tumor tissues has been connected to the early occurrence of the disease.

The research was carried out on patients with the mentioned disease as well as patients with bladder cancer, further deepened by rat experiments. Patients with cystitis glandularis and rats with cystitis exposed to E. coli both reported increased TPRG1 levels in their cystitis tissues. Injection of viral transmitters containing TPRG1 into cystitis rats suppressed the inflammatory response by lowering TPRG1 protein expression. The TPRG1 was silenced, which prevented an increase in cell number and cell movement.

The findings suggest that TPRG1 might be a novel therapeutic target for the treatment of cystitis glandularis. However, further research is required, since the drug’s safety in people with the disease should be investigated.

腺性膀胱炎是一種以慢性炎症和細胞快速分裂為特徵的膀胱疾病,可導致膀胱癌的進展。紹興大學和溫州醫科大學的科學家研究了腫瘤蛋白 TPRG1 在腺性膀胱炎中的作用,因為它與細胞對炎症的反應有關,並且其在腫瘤組織中的失調與疾病的早期發生有關。

該研究是針對患有上述疾病的患者以及患有膀胱癌的患者進行的,並通過大鼠實驗進一步深化。腺性膀胱炎患者和暴露於大腸桿菌的膀胱炎大鼠均報告其膀胱炎組織中 TPRG1 水平升高。將含有 TPRG1 的病毒遞質注射到膀胱炎大鼠中,通過降低 TPRG1 蛋白表達來抑制炎症反應。 TPRG1 被沉默,這阻止了細胞數量和細胞運動的增加。

研究結果表明,TPRG1 可能是治療腺性膀胱炎的新治療靶點。然而,還需要進一步的研究,因為應該調查藥物對患有疾病的人的安全性。

 

Reference: Hong T, Piao S, Sun L, Tao Y, Ke M. TPRG1 contributes to inflammation and cell proliferation of cystitis glandularis through regulating NF-кB/COX2/PGE2 axis. Bosn J of Basic Med Sci [Internet]. 2022Jan.7 [cited 2022Jan.16];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/6763.

Editor: Merima Bukva, MPharm

Be the first to comment

Leave a Reply

Your email address will not be published.


*